Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Details for Australian Patent Application No. 2005252217 (hide)
International Classifications
Event Publications
4 January 2007 PCT application entered the National Phase
PCT publication WO2005/121147 Priority application(s): WO2005/121147
15 April 2010 Assignment before Grant
Bayer Pharmaceuticals Corporation The application has been assigned to Bayer Healthcare LLC
12 May 2011 Application Accepted
Published as AU-B-2005252217
8 September 2011 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2005252220-Levodopa prodrugs, and compositions and uses thereof
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser